VVT Medical

What VVT Medical does

VVT Medical (V.V.T. Med Ltd) is an Israeli medical device company founded in 2004 and headquartered in Kfar Saba, Israel. The company develops and commercializes catheter-based, dual-mode mechanochemical systems — ScleroSafe and V-Block — for minimally invasive, non-thermal treatment of symptomatic varicose veins. Its core technology combines controlled sclerosant injection with simultaneous blood aspiration and vessel collapse, enabling anesthesia-free, in-office procedures without capital equipment requirements. ScleroSafe received FDA 510(k) clearance on June 20, 2023, and both products carry CE marking along with regulatory approvals in TGA (Australia), KFDA (South Korea), ANVISA (Brazil), AMAR (Israel), UAE, and CDSCO (India); V-Block is not available for sale in the United States. Clinical evidence includes a 2026 publication in the Indian Journal of Vascular and Endovascular Surgery from Holy Spirit Hospital in Mumbai demonstrating strong early vein closure rates and an excellent safety profile.

VVT Medical targets vascular surgeons, phlebologists, interventional radiologists, and other venous specialists across private phlebology clinics and hospital systems. Revenue is generated through hardware sales of its proprietary catheter-based devices via a hybrid go-to-market model: direct enterprise field sales in the United States — anchored by the first ScleroSafe procedure at Northwell Health's Vascular & Endovascular Vein Care Center on November 19, 2025 — combined with exclusive distribution partnerships internationally, including a five-year agreement with Medworks India (September 2025) and an exclusive arrangement with Antilles Medical in the Dominican Republic (June 2026). Pricing is quote-based and negotiated through sales channels rather than publicly disclosed.

The company completed a reverse takeover of DXI Capital Corp in November 2023 and listed on the TSX Venture Exchange (TSXv:VVTM) on November 26, 2025, to support US and global commercialization. It is in early commercialization with 1–10 employees and has raised approximately CAD $4 million across a March 2026 private placement of up to 12 million units at CAD $0.25 (gross proceeds up to $3 million) and a subsequent 2026 round, with proceeds earmarked for US and global commercialization, manufacturing expansion, and working capital.

Name

VVT Medical

Legal name

V.V.T. Med Ltd

Website

http://www.vvtmed.com

Company type

Public

Founded year

2004

Operating status

Operating

Headcount range

1–10 employees

Short description

VVT Medical is an Israeli medical device company developing catheter-based, dual-mode mechanochemical systems (ScleroSafe, V-Block) for minimally invasive, non-thermal varicose vein treatment, selling to vascular specialists worldwide via direct US field sales and exclusive international distributors, and trading on the TSX Venture Exchange (TSXv:VVTM).

Ownership category

akta.pro rank

Product category

Medical Devices — Varicose Vein Treatment

NAICS

Surgical and Medical Instrument Manufacturing (339112)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Vascular Access & Closure Devices (Sheaths, Guidewires, Closure Systems) (HLAHAFAK)

Keywords

• Varicose vein treatment
• Mechanochemical ablation
• Catheter-based devices
• Non-thermal venous therapy
• Minimally invasive vascular devices

Headquarters

HQ city

Kfar Saba

HQ country

Israel

HQ region

Middle East

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Medical Device Sales (ScleroSafe & V-Block): VVT Medical generates revenue through the sale of its proprietary catheter-based medical devices, ScleroSafe and V-Block, for minimally invasive varicose vein treatment. Both products are commercially available worldwide. Revenue is derived from direct sales to healthcare providers and through distribution channel partners in international markets.
2. Private Placement Financing: The company raised gross proceeds of up to $3 million through a non-brokered private placement of up to 12 million units at $0.25 per unit. Each unit consists of one common share and a half warrant exercisable at $0.375 for 24 months. Proceeds designated for U.S. and global commercialization, manufacturing expansion, and working capital.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels7 records

Core offering

VVT Medical develops and manufactures proprietary catheter-based medical devices for the minimally invasive, non-thermal treatment of symptomatic varicose veins. The portfolio consists of two synergistic products, ScleroSafe™ and V-Block™, both leveraging a dual-mode mechanochemical platform that combines controlled sclerosant injection with simultaneous vessel collapse and blood aspiration to enable anesthesia-free, in-office vein closure.

Product overview

VVT Medical develops and manufactures two proprietary catheter-based medical devices for minimally invasive, non-thermal treatment of varicose veins. The product portfolio consists of ScleroSafe™ (dual-mode mechano-chemical vein ablation system) and V-Block™ (biomedical implant with dual-mode technology). Both products leverage the same core mechanochemical technology combining controlled sclerosant injection with simultaneous blood aspiration and vessel collapse. ScleroSafe is FDA-cleared and commercially available worldwide, while V-Block is not available for sale in the United States. Both devices enable anesthesia-free, in-office treatments with immediate effect and minimal downtime.

Differentiator

Problem solved

Functional benefit

Products and services

• ScleroSafe™ Dual-mode mechano-chemical catheter-based system for vein ablation that combines controlled sclerosant injection with simultaneous vessel collapse and blood aspiration. FDA-cleared and CE-marked for minimally invasive varicose vein treatment in private clinics and hospital-based practices, targeting vascular surgeons, phlebologists, and interventional radiologists.
• V-Block™ Biomedical implant with dual-mode mechano-chemical vein ablation technology that allows physicians to treat a wider range of vein diameters, including large and challenging vessels, with precision and control. CE marked and commercially available outside the United States.

Quantifiable outcome

• Comparable closure rates to thermal procedures with non-thermal simplicity
• +3 more outcomes

Named customers3 records

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Three partnerships are on record, tiered core and key.

• Antilles MedicalcoreChannel Partner/ Reseller/ Distributor · 11 June 2026VVT Med Inc. appointed Antilles Medical as its exclusive distributor in the Dominican Republic following an evaluation period. The partnership represents VVT Med's continued commercial presence expansion in the Americas region, with potential for a long-term distribution agreement. Antilles Medical will distribute VVT Med's FDA-cleared and CE-marked catheter-based technologies (ScleroSafe and V-Block) for minimally invasive treatment of varicose veins.
• Northwell HealthkeyStrategic or Co-development Partner · 19 November 2025Northwell Health, one of the largest healthcare systems in the US, performed its first-ever ScleroSafe procedure at the Vascular & Endovascular Vein Care Center in New York. Dr. Antonios Gasparis, System Chief of Vein Disease, led the procedure. Northwell represents a key reference customer and potential KOL partnership for US market development.
• Medworks IndiacoreChannel Partner/ Reseller/ Distributor · 1 September 2025VVT Medical entered into a five-year distribution agreement with Medworks India for the commercialization of its ScleroSafe platform. Medworks, a leading healthcare distributor in India, is responsible for the marketing, sales, and distribution of ScleroSafe across the Indian market, leveraging its established network and deep expertise in advanced healthcare technologies.

Scale indicators6 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• AngioDynamics: Medical device company with a portfolio of endovenous laser ablation products (VenaCure EVLT) and other venous therapy offerings. Competes directly with ScleroSafe in physician clinics and ambulatory surgery centers offering varicose vein treatment.
• Abbott Vascular: Abbott's cardiovascular division offers peripheral vascular intervention products targeting vascular specialists. Comparable as a deep-pocketed incumbent competing for the same vascular surgeon and interventional radiologist procedure volumes as VVT Medical.
• Boston Scientific: Large diversified medical device company active in vascular interventions including varicose vein therapies. Serves the same vascular surgeon and interventional radiology customer base as VVT with broader portfolio reach and substantially greater commercialization scale.
• Medtronic: Global medical device incumbent offering the VenaSeal cyanoacrylate closure system and ClosureFast radiofrequency ablation system for varicose veins. Competes head-to-head with ScleroSafe for physician adoption and hospital contracts, with vastly larger field sales, clinical evidence, and capital resources.
• Teleflex: Diversified medical device manufacturer with vascular access and surgical product lines serving hospitals and outpatient settings. Comparable as a catheter-based device company with established US sales channels into the same hospital call points as VVT.

Emerging players

• Inari Medical: Specialist venous intervention company initially focused on venous thromboembolism, with growing peripheral vascular presence. Comparable as a focused venous specialist pursuing physician share in the same specialty call point as VVT Medical.
• Penumbra: Developer of the Indigo mechanical thrombectomy system for venous and arterial clot removal, with expanding peripheral vascular portfolio. Comparable as a US-listed catheter-based vascular intervention company targeting similar specialist physicians.

Others

• Merit Medical Systems: Medical device company with a peripheral vascular and embolotherapy portfolio serving interventional radiologists and vascular surgeons. Comparable as a catheter-based vascular intervention company addressing the same hospital call point where VVT targets procedure volume.
• BTG (now Boston Scientific): Acquired by Boston Scientific in 2019, BTG previously offered varicose vein ablation products including the VariClose platform. Relevant as a comparable precedent for how a niche venous specialist is absorbed by an incumbent, shaping potential exit pathways for VVT.

Direct peers

• Vascular Insights: Developer of the Clarivein mechanochemical ablation catheter for varicose veins. Closest direct competitor to VVT's ScleroSafe, using a rotating wire plus sclerosant delivery mechanism to achieve vein closure — directly overlapping on indication, mechanism, and physician target.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xtwitter.com/VVTMedicalLtd
• YouTubeyoutube.com/channel/UCqzVKyULhJl4_1dy4BLrOBQ
• Facebookfacebook.com/VVTMedical
• LinkedInlinkedin.com/company/vvt-medical
• Instagraminstagram.com/vvt_medical
• TikToktiktok.com/@vvtmedical?lang=en

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about VVT Medical